Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet.
作者信息
Garrow J
出版信息
BMJ. 1998 Sep 26;317(7162):830-1. doi: 10.1136/bmj.317.7162.830.
Abstract
摘要
相似文献
1
Flushing away the fat. Weight loss during trials of orlistat was significant, but over half was due to diet.排走脂肪。在奥利司他试验期间体重减轻显著，但超过一半是由于节食。
BMJ. 1998 Sep 26;317(7162):830-1. doi: 10.1136/bmj.317.7162.830.
2
The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.奥利司他在肥胖症、血脂异常和2型糖尿病治疗中的应用。
Expert Opin Pharmacother. 2005 Nov;6(14):2483-91. doi: 10.1517/14656566.6.14.2483.
3
First clinical studies with orlistat: a short review.奥利司他的首次临床研究：简要综述。
Obes Res. 1995 Nov;3 Suppl 4:623S-625S. doi: 10.1002/j.1550-8528.1995.tb00236.x.
4
Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.奥利司他，一种脂肪酶抑制剂，用于传统节食后的体重维持：一项为期1年的研究。
Am J Clin Nutr. 1999 Jun;69(6):1108-16. doi: 10.1093/ajcn/69.6.1108.
5
Orlistat and weight loss.
Lancet. 1998 Oct 31;352(9138):1473; author reply 1474. doi: 10.1016/S0140-6736(05)61300-1.
6
[Pharmacotherapy in the treatment of obesity].[肥胖症治疗中的药物疗法]
MMW Fortschr Med. 2006 Mar 2;148(9):36-8. doi: 10.1007/BF03364581.
7
Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.奥利司他治疗肥胖受试者2年的体重控制及危险因素降低：一项随机对照试验
JAMA. 1999 Jan 20;281(3):235-42. doi: 10.1001/jama.281.3.235.
8
Treatment with orlistat reduces cardiovascular risk in obese patients.使用奥利司他治疗可降低肥胖患者的心血管疾病风险。
J Hypertens. 1998 Dec;16(12 Pt 2):2013-7. doi: 10.1097/00004872-199816121-00024.
9
Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.奥利司他，一种胃肠道脂肪酶抑制剂，用于治疗伴有高脂血症的肥胖症。
Med Pregl. 1999 Sep-Oct;52(9-10):323-33.
10
New aspects in the management of obesity: operation and the impact of lipase inhibitors.肥胖管理的新进展：手术及脂肪酶抑制剂的影响
Curr Opin Lipidol. 1999 Feb;10(1):3-7. doi: 10.1097/00041433-199902000-00002.
引用本文的文献
1
Orlistat: a review of its use in the management of patients with obesity.奥利司他：对其在肥胖症患者管理中的应用综述。
Drugs. 2004;64(24):2845-64. doi: 10.2165/00003495-200464240-00010.
2
Orlistat: a review of its use in the management of obesity.奥利司他：对其在肥胖管理中应用的综述
Drugs. 1999 Oct;58(4):743-60. doi: 10.2165/00003495-199958040-00015.
本文引用的文献
1
Obesity: preventing and managing the global epidemic. Report of a WHO consultation.肥胖：预防和管理全球流行疾病。世界卫生组织磋商报告。
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253.
2
Randomised controlled trial of novel, simple, and well supervised weight reducing diets in outpatients.门诊患者新型、简单且监管良好的减肥饮食随机对照试验。
BMJ. 1998 Nov 28;317(7171):1487-9. doi: 10.1136/bmj.317.7171.1487.
3
Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.奥利司他用于肥胖患者减肥及预防体重反弹的随机安慰剂对照试验。欧洲多中心奥利司他研究小组。
Lancet. 1998 Jul 18;352(9123):167-72. doi: 10.1016/s0140-6736(97)11509-4.
4
A survey of heights and weights of adults in Great Britain, 1980.
Ann Hum Biol. 1985 Mar-Apr;12(2):115-27. doi: 10.1080/03014468500007621.
5
International trial of long-term dexfenfluramine in obesity.
Lancet. 1989 Nov 11;2(8672):1142-5. doi: 10.1016/s0140-6736(89)91499-2.
6
Explanations for weight loss after ileojejunal bypass in gross obesity.
Br Med J. 1976 Jun 19;1(6024):1504-5. doi: 10.1136/bmj.1.6024.1504.
Zotero 插件